Leonardo Daniel Garma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonardo Daniel Garma has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Quintela-Fandino
Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain
15 shared publications - Juan Antonio Guerra
Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
10 shared publications - Alfonso Cortés-Salgado
Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Universidad de Alcalá, Medical Oncology Department, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
9 shared publications - Jose Angel Garcia Saenz
GEICAM, Spanish Breast Cancer Group, Madrid, Spain
9 shared publications - Juan Miguel Cejalvo
Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; Department of Medical Oncology, Breast Cancer Biology Research Group, Biomedical Research Institute INCLIVA, Valencia, Spain
9 shared publications - Lucía González-Cortijo
Medical Oncology Department, Hospital Universitario Quironsalud, Madrid, Spain
9 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Taylor & Francis in Epigenetics
- Vol. 21 (1)
A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples
Aging is a major risk factor for numerous diseases [1,2], and amongst the largest risk factors for cancer [3]. As women age, their risk of developing breast cancer increases substantially, with inc...
- 11 September 2026
- Published by Taylor & Francis in Epigenetics
- Vol. 21 (1)
Open AccessA breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples
Aging is a major risk factor for numerous diseases [1,2], and amongst the largest risk factors for cancer [3]. As women age, their risk of developing breast cancer increases substantially, with inc...
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Longitudinal Clinical, Physiological, and Molecular Profiling of Female Patients With Metastatic Cancer: Protocol and Feasibility of a Multicenter High-Definition Oncology Study
PURPOSE: A substantial proportion of patients receiving genomically matched therapies do not achieve clinical benefit, underscoring the influence of nongenetic factors on cancer outcomes. High-Definition Oncology (HDO) proposes integrating longitudinal, multimodal patient data—spanning clinical, molecular, physiological, and behavioral domains—to enable truly individualized cancer care. This manuscript describes the HDO study design, framework, and feasibility results in women with metastatic cancer. METHODS: We initiated a prospective, multicenter observational study (HDO study; ClinicalTrials.gov identifier: NCT06590506 ) enrolling 300 female patients with newly diagnosed metastatic breast, lung, or colorectal cancer. Here, we report the study design, standardized workflows, prespecified feasibility criteria, and early internal pilot results. Eleven data modalities are collected longitudinally, including tumor and germline genomics, germline epigenomics, gut microbiome, blood and stool metabolomics and proteomics, exposome characterization, wearable-derived physiological monitoring, digital footprint assessment, medical imaging, and patient-reported outcomes. Standardized workflows govern clinical procedures, data acquisition, biospecimen processing, and quality control across all participating sites. RESULTS: Feasibility was evaluated in the first 30 participants (10% of planned accrual). Patients completed 100% of scheduled clinical visits, 97.4% of planned plasma collections, 80.7% of stool samples, and all tumor biopsies. Wearable devices captured activity, heart rate, sleep, and blood oxygen saturation data during 95.0%, 84.2%, 90.6%, and 70.7% of total patient-days, respectively. Biospecimens met predefined quality control metrics across all molecular modalities. Engagement with mobile applications for pain and emotion reporting exceeded 80%. CONCLUSION: The HDO study demonstrates the feasibility of comprehensive, longitudinal, multimodal data collection in women with metastatic cancer. This internal pilot establishes an integrated framework for future analyses aimed at characterizing disease trajectories, defining molecular and physiological determinants of outcomes, and developing patient-specific computational models.
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Longitudinal Clinical, Physiological, and Molecular Profiling of Female Patients With Metastatic Cancer: Protocol and Feasibility of a Multicenter High-Definition Oncology Study
PURPOSE: A substantial proportion of patients receiving genomically matched therapies do not achieve clinical benefit, underscoring the influence of nongenetic factors on cancer outcomes. High-Definition Oncology (HDO) proposes integrating longitudinal, multimodal patient data—spanning clinical, molecular, physiological, and behavioral domains—to enable truly individualized cancer care. This manuscript describes the HDO study design, framework, and feasibility results in women with metastatic cancer. METHODS: We initiated a prospective, multicenter observational study (HDO study; ClinicalTrials.gov identifier: NCT06590506 ) enrolling 300 female patients with newly diagnosed metastatic breast, lung, or colorectal cancer. Here, we report the study design, standardized workflows, prespecified feasibility criteria, and early internal pilot results. Eleven data modalities are collected longitudinally, including tumor and germline genomics, germline epigenomics, gut microbiome, blood and stool metabolomics and proteomics, exposome characterization, wearable-derived physiological monitoring, digital footprint assessment, medical imaging, and patient-reported outcomes. Standardized workflows govern clinical procedures, data acquisition, biospecimen processing, and quality control across all participating sites. RESULTS: Feasibility was evaluated in the first 30 participants (10% of planned accrual). Patients completed 100% of scheduled clinical visits, 97.4% of planned plasma collections, 80.7% of stool samples, and all tumor biopsies. Wearable devices captured activity, heart rate, sleep, and blood oxygen saturation data during 95.0%, 84.2%, 90.6%, and 70.7% of total patient-days, respectively. Biospecimens met predefined quality control metrics across all molecular modalities. Engagement with mobile applications for pain and emotion reporting exceeded 80%. CONCLUSION: The HDO study demonstrates the feasibility of comprehensive, longitudinal, multimodal data collection in women with metastatic cancer. This internal pilot establishes an integrated framework for future analyses aimed at characterizing disease trajectories, defining molecular and physiological determinants of outcomes, and developing patient-specific computational models.
- Open Access
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti–PD-L1 refractoriness in breast cancer models
Resistance to antiangiogenics is a major challenge in cancer therapy. These agents can either normalize or exacerbate tumor vascular abnormality and hypoxia. The mechanisms of resistance remain unclear in the latter setting. By integrating data from mouse models and clinical trials, we showed that hypoxia-inducing anti-VEGF therapy upregulated programmed cell death ligand 1 (PD-L1), yet failed to sensitize tumors to PD-L1 blockade. Mechanistically, early hypoxic stress triggered epithelial osteopontin (SPP1) production, which recruited monocytes and skewed macrophages toward M2 states, suppressing T cell cytotoxicity. Pharmacological SPP1 depletion impeded the development of hypoxia, reduced M2 infiltration, restored T cell activity, and enabled synergy between antiangiogenics and anti–PD-L1. Genetic dissection — tumor-epithelial Spp1 -KO grafts and bone marrow chimeras generated by lethal irradiation and reconstitution with Spp1 –/– or WT hematopoietic donors — showed that myeloid SPP1 contributed only marginally compared with epithelial SPP1. These findings identified SPP1 as a central mediator of resistance to hypoxia-inducing antiangiogenics, contributed to a comprehensive model of antiangiogenic resistance, and supported SPP1-targeted strategies to personalize immunotherapy and antiangiogenic therapy according to tumor hypoxia.
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Open AccessOsteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti–PD-L1 refractoriness in breast cancer models
Resistance to antiangiogenics is a major challenge in cancer therapy. These agents can either normalize or exacerbate tumor vascular abnormality and hypoxia. The mechanisms of resistance remain unclear in the latter setting. By integrating data from mouse models and clinical trials, we showed that hypoxia-inducing anti-VEGF therapy upregulated programmed cell death ligand 1 (PD-L1), yet failed to sensitize tumors to PD-L1 blockade. Mechanistically, early hypoxic stress triggered epithelial osteopontin (SPP1) production, which recruited monocytes and skewed macrophages toward M2 states, suppressing T cell cytotoxicity. Pharmacological SPP1 depletion impeded the development of hypoxia, reduced M2 infiltration, restored T cell activity, and enabled synergy between antiangiogenics and anti–PD-L1. Genetic dissection — tumor-epithelial Spp1 -KO grafts and bone marrow chimeras generated by lethal irradiation and reconstitution with Spp1 –/– or WT hematopoietic donors — showed that myeloid SPP1 contributed only marginally compared with epithelial SPP1. These findings identified SPP1 as a central mediator of resistance to hypoxia-inducing antiangiogenics, contributed to a comprehensive model of antiangiogenic resistance, and supported SPP1-targeted strategies to personalize immunotherapy and antiangiogenic therapy according to tumor hypoxia.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Representativeness of Study Participants table
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Representativeness of Study Participants table
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Trial schedule and CONSORT diagram. A, Basic trial schedule. Prescreened patients positive for either p-ERK and/or CDK6 were eligible after experiencing RECIST v1.1 disease progression to their first or second treatment line for advanced disease. Treatment consisted of continuous binimetinib (45 mg orally twice a day) and palbociclib (100 mg/day, orally) from days 1 to 21 of 28-day cycles. Palbociclib was allowed to be escalated to 125 mg/day in case of patients showing acceptable tolerance to 100/day during cycle 1. Treatment continued until disease progression, unacceptable toxicity, or investigator decision. D, day. B, CONSORT diagram. * The most frequent reasons for not meeting inclusion criteria were having received less than one or more than two treatment lines for advanced TNBC (n = 9), not having experienced disease progression to the previous treatment line according to RECIST v1.1 (n = 9), and inadequate organ function (n = 2). Eval., evaluation.
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Trial schedule and CONSORT diagram. A, Basic trial schedule. Prescreened patients positive for either p-ERK and/or CDK6 were eligible after experiencing RECIST v1.1 disease progression to their first or second treatment line for advanced disease. Treatment consisted of continuous binimetinib (45 mg orally twice a day) and palbociclib (100 mg/day, orally) from days 1 to 21 of 28-day cycles. Palbociclib was allowed to be escalated to 125 mg/day in case of patients showing acceptable tolerance to 100/day during cycle 1. Treatment continued until disease progression, unacceptable toxicity, or investigator decision. D, day. B, CONSORT diagram. * The most frequent reasons for not meeting inclusion criteria were having received less than one or more than two treatment lines for advanced TNBC (n = 9), not having experienced disease progression to the previous treatment line according to RECIST v1.1 (n = 9), and inadequate organ function (n = 2). Eval., evaluation.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Efficacy results. A, Kaplan–Meier (KM) curve and (B) swimmer plot displaying PFS time for the efficacy population (N = 23). C, Waterfall plot showing the best overall response for the 16 patients with measurable disease. The mutational status of the most frequently mutated genes in TNBC is shown underneath the waterfall plot. D, Spider plot of the efficacy population.
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Efficacy results. A, Kaplan–Meier (KM) curve and (B) swimmer plot displaying PFS time for the efficacy population (N = 23). C, Waterfall plot showing the best overall response for the 16 patients with measurable disease. The mutational status of the most frequently mutated genes in TNBC is shown underneath the waterfall plot. D, Spider plot of the efficacy population.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Data from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Purpose:Advanced, pretreated triple-negative breast cancer (TNBC) has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that cyclin-dependent kinase 6 (CDK6) and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg twice a day) plus palbociclib (100 mg daily, days 1–21) in 28-day cycles. Palbociclib escalation to 125 mg was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month–long progression-free survival (PFS), a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequencing was performed in tumor samples of the efficacy population.Results:Fifty-one patients were screened, of whom 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia, and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4 to 13 months. Whole-exome sequencing revealed a distinct mutational landscape among long-term responders compared with early progressors.Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. Whereas CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.Significance:Previous studies showed that patients with early TNBC with increased CDK4/6 and ERK activity are at high risk of relapse. Preclinical data also suggest the benefit of combined inhibition of CDK4/6 and MEK, and novel therapies are needed for TNBC in the advanced disease setting. Despite the rationale and a biomarker-driven design, this combination was toxic and showed limited efficacy. This combination should not be further developed in this disease.
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Purpose:Advanced, pretreated triple-negative breast cancer (TNBC) has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that cyclin-dependent kinase 6 (CDK6) and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg twice a day) plus palbociclib (100 mg daily, days 1–21) in 28-day cycles. Palbociclib escalation to 125 mg was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month–long progression-free survival (PFS), a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequencing was performed in tumor samples of the efficacy population.Results:Fifty-one patients were screened, of whom 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia, and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4 to 13 months. Whole-exome sequencing revealed a distinct mutational landscape among long-term responders compared with early progressors.Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. Whereas CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.Significance:Previous studies showed that patients with early TNBC with increased CDK4/6 and ERK activity are at high risk of relapse. Preclinical data also suggest the benefit of combined inhibition of CDK4/6 and MEK, and novel therapies are needed for TNBC in the advanced disease setting. Despite the rationale and a biomarker-driven design, this combination was toxic and showed limited efficacy. This combination should not be further developed in this disease.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure S1 shows CDK6 and p-ERK positivity in screened samples
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure S1 shows CDK6 and p-ERK positivity in screened samples
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Correlative studies. A, Dot plot showing the correlation between CDK6 and (B) p-ERK staining (Z-score) and PFS time. The Pearson coefficients were −0.158 (P = 0.472) and 0.143 (P = 0.514). C, Mutational status of HR genes among patients with short (4 months) progression-free interval. Dark color indicates WT status of both alleles; green indicates a heterozygous deleterious mutation, and yellow indicates deleterious alterations in both alleles. D, Heatmap depicting the genes with differential mutational pattern between patients with short or long PFS, listed by their T test score. Darker colors indicate none or lower number of deleterious mutations across their exome, whereas lighter colors indicate increased number of deleterious mutations (up to 5).
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Correlative studies. A, Dot plot showing the correlation between CDK6 and (B) p-ERK staining (Z-score) and PFS time. The Pearson coefficients were −0.158 (P = 0.472) and 0.143 (P = 0.514). C, Mutational status of HR genes among patients with short (4 months) progression-free interval. Dark color indicates WT status of both alleles; green indicates a heterozygous deleterious mutation, and yellow indicates deleterious alterations in both alleles. D, Heatmap depicting the genes with differential mutational pattern between patients with short or long PFS, listed by their T test score. Darker colors indicate none or lower number of deleterious mutations across their exome, whereas lighter colors indicate increased number of deleterious mutations (up to 5).